How Anovo Builds Dedicated Teams to Support Your Rare Disease Therapy
At Anovo, we understand that complex rare disease therapies require high-touch service that large payer- and Pharmacy Benefit Manager-owned Specialty…
Justin’s Story: Living with Duchenne Muscular Dystrophy
When Justin was first diagnosed with Duchenne muscular dystrophy, his parents, Amanda and Andrew, weren’t sure how to navigate the…
January 14, 2025
Eton Pharmaceuticals & Anovo Partner to Expand Access for Patients with Severe Primary Insulin-Like Growth Factor 1 Deficiency
Eton Pharmaceuticals is dedicated to developing and commercializing treatments for rare diseases, with a strong focus on pediatric endocrinology. Their…
December 20, 2024
Jaette’s Story: Living with Rett Syndrome
Siri’s mom, Jaette, has been navigating the challenges of Rett syndrome since her daughter’s diagnosis at four years old. In…
October 22, 2024
Supporting Innovative ALS Treatments with Clene Nanomedicine & Synapticure
Anovo is proud to announce a new partnership with Clene Nanomedicine, Inc. and Synapticure Inc., supporting their efforts to bring…
October 14, 2024
Cycle Pharmaceuticals and Anovo Deliver Relief to Those with Homozygous Cystinuria
Cycle Pharmaceuticals was founded in 2012 with one mission in mind: delivering best-in-class drug treatments and services to the underserved…
July 29, 2024
Advancing Rare Disease Care: Insights from the World Orphan Drug Congress and AAN Annual Meeting
The World Orphan Drug Congress (WODC) and the American Academy of Neurology (AAN) Annual Meeting are where healthcare leaders, advocates,…
June 11, 2024
Pyros and Anovo Partner to Elevate Care for Infantile Spasms
Pyros Pharmaceuticals works to elevate the standard of care for children with rare disease by pioneering treatment options like VIGPODER™…
April 1, 2024
Jill’s Story: Advocating for Patients with Acromegaly
Jill Sisco isn’t just an advocate – she’s also a patient herself. She’s been living with Acromegaly, a rare disease…
March 6, 2024
Celebrating Five Consecutive Years as a Top Workplace at Anovo
We are thrilled to announce that Anovo has been recognized as a top workplace by The Commercial Appeal for the…
February 6, 2024
FDA Releases Final Guidance on Rare Disease Drug Development
The FDA recently released its final guidance on rare disease drug development, which will have several significant implications for orphan…
January 4, 2024
Egetis Therapeutics & Anovo Unite for MCT8 Patients
Egetis Therapeutics is an innovative pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases…
January 2, 2024
Braynelle’s Story: Living with Dravet Syndrome
Braynelle and Brandon have been managing their son Kai’s diagnosis of Dravet Syndrome since he was four months old. After…
December 3, 2023
Scott’s Story: Living with Lambert-Eaton Myasthenic Syndrome
Experience Scott’s extraordinary journey living with Lambert-Eaton myasthenic syndrome (LEMS), where for over a decade, he’s been his own advocate,…
November 15, 2023
Kevin’s Story: Living with Lambert-Eaton Myasthenic Syndrome
Meet Kevin, an Anovo patient living with Lambert-Eaton myasthenic syndrome. Despite the challenges he’s faced in not always being able…
November 1, 2023
Acadia and Anovo Partner to Transform Rett Syndrome Care
Acadia Pharmaceuticals, Inc. is a pioneering biopharmaceutical company dedicated to transforming the treatment landscape for central nervous system (CNS) disorders….
October 3, 2023
Anovo Recognized for Creation of “End-to-End” Service Model that Benefits Both Patients and Manufacturers
Anovo is excited to announce that we have been featured in an article for USA Today, which details our unique…
September 5, 2023
